Under the agreement, Almirall is granted global rights to develop and commercialize ISB 880, monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.
Lead Product(s): ISB 880
Therapeutic Area: Immunology Product Name: ISB 880
Highest Development Status: IND Enabling Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: $23.6 million
Deal Type: Licensing Agreement December 14, 2021
Regulatory authorities in France, the Netherlands and the UK have approved the clinical trial application for a phase I/IIa study of PN?1007 for the treatment of anti-MAG neuropathy.
Lead Product(s): PN-1007
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020